In what has been touted as the biggest and best biotech licensing deal in history, Bristol-Myers Squibb (BMS) and Nektar Therapeutics (Nektar) recently agreed to terms of a Global Development & Commercialisation Collaboration, to work on Nektar’s lead oncology program, the CD122-biased agonist, NKTR-214. NKTR-214 is going to be used in combination therapies with BMS’s flagship OPDIVO ® (nivolumab) antibody melanoma … Continue reading Is the recent BMS-Nektar NKTR-214 deal really the most lucrative agreement in biotech history?